Literature DB >> 11083853

Disease outcome subsequent to primary and secondary urogenital infection with murine or human biovars of Chlamydia trachomatis.

K H Ramsey1, J L DeWolfe, R D Salyer.   

Abstract

A susceptible strain of mice infected intravaginally with the mouse pneumonitis biovar of Chlamydia trachomatis became infertile and sustained high rates of hydrosalpinx formation regardless of prior infection with a human serovar. Conversely, susceptible mice infected with human serovars remained fertile unless challenged with a homologous human serovar.

Entities:  

Mesh:

Year:  2000        PMID: 11083853      PMCID: PMC97838          DOI: 10.1128/IAI.68.12.7186-7189.2000

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  14 in total

1.  Differential sensitivity of distinct Chlamydia trachomatis isolates to IFN-gamma-mediated inhibition.

Authors:  L L Perry; H Su; K Feilzer; R Messer; S Hughes; W Whitmire; H D Caldwell
Journal:  J Immunol       Date:  1999-03-15       Impact factor: 5.422

2.  Long-term follow-up of the initial (1959-1960) trachoma vaccine field trial on Taiwan.

Authors:  R L Woolridge; J T Grayston; I H Chang; C Y Yang; K H Cheng
Journal:  Am J Ophthalmol       Date:  1967-05       Impact factor: 5.258

3.  Mouse strain-dependent variation in the course and outcome of chlamydial genital tract infection is associated with differences in host response.

Authors:  T Darville; C W Andrews; K K Laffoon; W Shymasani; L R Kishen; R G Rank
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

4.  Dissemination of Chlamydia trachomatis chronic genital tract infection in gamma interferon gene knockout mice.

Authors:  T W Cotter; K H Ramsey; G S Miranpuri; C E Poulsen; G I Byrne
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

5.  Prior genital tract infection with a murine or human biovar of Chlamydia trachomatis protects mice against heterotypic challenge infection.

Authors:  K H Ramsey; T W Cotter; R D Salyer; G S Miranpuri; M A Yanez; C E Poulsen; J L DeWolfe; G I Byrne
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

6.  Increased incidence of oviduct pathology in the guinea pig after repeat vaginal inoculation with the chlamydial agent of guinea pig inclusion conjunctivitis.

Authors:  R G Rank; M M Sanders; D L Patton
Journal:  Sex Transm Dis       Date:  1995 Jan-Feb       Impact factor: 2.830

7.  Intravaginal inoculation of mice with the Chlamydia trachomatis mouse pneumonitis biovar results in infertility.

Authors:  L M de la Maza; S Pal; A Khamesipour; E M Peterson
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

8.  Demonstration of delayed hypersensitivity in Chlamydia trachomatis salpingitis in monkeys: a pathogenic mechanism of tubal damage.

Authors:  D L Patton; Y T Sweeney; C C Kuo
Journal:  J Infect Dis       Date:  1994-03       Impact factor: 5.226

Review 9.  Chlamydia trachomatis antigens: role in immunity and pathogenesis.

Authors:  R C Brunham; R W Peeling
Journal:  Infect Agents Dis       Date:  1994-10

10.  ISOLATION FROM NORMAL MICE OF A PNEUMOTROPIC VIRUS WHICH FORMS ELEMENTARY BODIES.

Authors:  C Nigg; M D Eaton
Journal:  J Exp Med       Date:  1944-05-01       Impact factor: 14.307

View more
  13 in total

Review 1.  Vaccination against Chlamydia genital infection utilizing the murine C. muridarum model.

Authors:  Christina M Farris; Richard P Morrison
Journal:  Infect Immun       Date:  2010-11-15       Impact factor: 3.441

2.  Chlamydia trachomatis persistence in the female mouse genital tract: inducible nitric oxide synthase and infection outcome.

Authors:  K H Ramsey; G S Miranpuri; I M Sigar; S Ouellette; G I Byrne
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

3.  Specific-pathogen-free pigs as an animal model for studying Chlamydia trachomatis genital infection.

Authors:  Daisy Vanrompay; Thi Q T Hoang; Liselotte De Vos; Kristel Verminnen; Taher Harkinezhad; Koen Chiers; Servaas A Morré; Eric Cox
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

4.  Differences in growth characteristics and elementary body associated cytotoxicity between Chlamydia trachomatis oculogenital serovars D and H and Chlamydia muridarum.

Authors:  J M Lyons; J I Ito; A S Peña; S A Morré
Journal:  J Clin Pathol       Date:  2005-04       Impact factor: 3.411

Review 5.  Animal models for studying female genital tract infection with Chlamydia trachomatis.

Authors:  Evelien De Clercq; Isabelle Kalmar; Daisy Vanrompay
Journal:  Infect Immun       Date:  2013-07-08       Impact factor: 3.441

6.  Murine Chlamydia trachomatis genital infection is unaltered by depletion of CD4+ T cells and diminished adaptive immunity.

Authors:  Sandra G Morrison; Christina M Farris; Gail L Sturdevant; William M Whitmire; Richard P Morrison
Journal:  J Infect Dis       Date:  2011-02-14       Impact factor: 5.226

7.  Vaccination with the recombinant major outer membrane protein elicits antibodies to the constant domains and induces cross-serovar protection against intranasal challenge with Chlamydia trachomatis.

Authors:  Delia F Tifrea; Pooja Ralli-Jain; Sukumar Pal; Luis M de la Maza
Journal:  Infect Immun       Date:  2013-03-11       Impact factor: 3.441

8.  Differences in infectivity and induction of infertility: a comparative study of Chlamydia trachomatis strains in the murine model.

Authors:  Jennifer R Carmichael; Delia Tifrea; Sukumar Pal; Luis M de la Maza
Journal:  Microbes Infect       Date:  2012-12-31       Impact factor: 2.700

9.  Transcervical Mouse Infections with Chlamydia trachomatis and Determination of Bacterial Burden.

Authors:  Karthika Rajeeve; Rajeeve Sivadasan
Journal:  Bio Protoc       Date:  2020-02-05

10.  Acquired homotypic and heterotypic immunity against oculogenital Chlamydia trachomatis serovars following female genital tract infection in mice.

Authors:  Joseph M Lyons; Servaas A Morré; Lucy P Airo-Brown; A Salvador Peña; James I Ito
Journal:  BMC Infect Dis       Date:  2005-11-17       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.